Trial NCT00107471

View at ClinicalTrials.gov 
Org. Study IDs: ACNS0224
Secondary IDs: CDR0000417842 COG-ACNS0224

Last trial update was posted on 2013-12-10

MeSH Interventions

Lenograstim Topotecan

MeSH Conditions

Central Nervous System Neoplasms Glioma Nervous System Neoplasms

Other Conditions

Brain Tumors Central Nervous System Tumors

Stopping Reasons

The unpromising experience of the French group with topotecan given at a dosage of 0.4 mg/m2/day over 30 mins w/in 1 hr of radiation (Cancer 2005; 104: 2792).

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID